Company intelligence / Profile preview

Talima Therapeutics

San Carlos, California, United Statestalima.com ↗

Ownership: Private
Employees: ~1
Development stage: Other

Overview

Talima Therapeutics developed a proprietary micro‐implant technology enabling site-specific drug delivery to optimize therapeutic performance and minimize systemic side effects. Their initial clinical focus was dermatology—specifically onychomycosis, psoriasis, and acne—using proven drugs reformulated for local application. The company secured $19 million in Series B funding in May 2007 to advance its lead program into Phase II trials. There are no recent clinical results or product launches reported after this period.

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Drug delivery systems (notably micro-implants)local drug delivery
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on Talima Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Talima Therapeutics.